Australia to begin human trials for COVID-19 vaccine made by China
Category: #headlines  By Saipriya Iyer  Date: 2020-04-29
  • share
  • Twitter
  • Facebook
  • LinkedIn
Australia to begin human trials for COVID-19 vaccine made by China

Linear Clinical Research, a research and clinical facility in Perth, Australia, has confirmed a human trial of a coronavirus vaccine that has been developed by China. Sources familiar with the matter said that research and clinical facility has already initiated the recruitment of healthy adults to participate in the trial within the coming two months.

S-Trimer vaccine, which is primarily developed by a biotechnology company called Clover Biopharmaceuticals, located in China, is believed to be one of the first COVID-19 vaccines to be under development. Linear had also made an announcement regarding the vaccine trial on the website and also called on the people who are interested in being registered with the company.

The company issued the statement that if people were feeling unhealthy and were located in Perth, WA, they could register their interest to be able to participate in the forthcoming COVID-19 vaccine study of the company.

According to a reliable source, the protein-based vaccine S-Trimer, is aimed at helping the body in producing anti-bodies to fight the virus.

Jayden Rogers, Linear’s chief executive commented that the trial was among the most vital trials across the globe and involves some extremely renowned vaccine firms. The S-Trimer vaccine had shown promising potential on the trial and has been placed at the forefront of the world’s battle with coronavirus pandemic.

The Chinese authorities had approved the human testing for two other COVID-19 vaccines recently in the month of April that were developed by the Wuhan Institute of Biological Products. This was done under the Sinovac Research and Development Co and China National Pharmaceutical Group (Sinopharm).

Apparently, Sinopharm has been able to produce more than 50,000 doses for the clinical trials. Once the production gets normalized, the output is capable of reaching about 3 million doses per batch and an annual output would be at 100 million doses.

 

Source Credit- https://www.aa.com.tr/en/asia-pacific/australia-set-for-chinese-covid-19-vaccine-human-trial-/1821328

 

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

Sequitur Labs officially joins the NVIDIA Partner Network
Sequitur Labs officially joins the NVIDIA Partner Network
By Saipriya Iyer

Sequitur Labs, a seminal technologies and solutions developer, has reportedly announced that it joined the NVIDIA Partner Network, an innovative platform of the renowned visual computing solutions provider, with complete support for the NVIDIA Jetson...

American Equity & Brookfield Asset Management ink new partnership deal
American Equity & Brookfield Asset Management ink new partnership deal
By Saipriya Iyer

American Equity Investment Life Holding Company, a renowned and leading US based life insurance firm, has reportedly announced a new strategic collaboration with a top Canadian alternative asset management firm, Brookfield Asset Management. The compa...

Arrival to set up its first U.S. EV factory in South Carolina
Arrival to set up its first U.S. EV factory in South Carolina
By Saipriya Iyer

Arrival, a London based electric vehicle (EV) manufacturer, has reportedly announced that it would be building its first U.S-based micro factory in York County of South Carolina. The company plans to initiate production operations at the facility dur...